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Since	 the	 discovery	 of	 the	 lysophospholipid-sensitive	 receptor	 GPR55,	 hopes	18	
have	been	 raised	 that	 targeting	 this	GPCR	may	 represent	 a	novel	 approach	 for	19	
the	 treatment	 of	 metabolic	 disorders.	 Here,	 we	 discuss	 conflicting	 evidence	20	












Excessive	 intake	of	 rich,	non-nutritious	 foods	can	result	 in	metabolic	disorders	33	
such	 as	 obesity	 and	 related	 comorbidities,	 including	 type	 2	 diabetes	 mellitus	34	
(T2DM).	As	obesity	 levels	continue	 to	rise,	development	of	new	therapeutics	 is	35	
crucial	for	the	slowing	or	reversal	of	this	escalating	epidemic.		36	
	37	
One	 physiological	 system	 that	 may	 be	 therapeutically	 exploited	 to	 control	38	
obesity	is	the	endocannabinoid	system	(ECS).	This	system	classically	consists	of	39	




insulin	 sensitivity,	 glucose	 homeostasis	 and	 fat	 accumulation	 [1].	 Cannabinoid	44	
agonists	increase	the	desire	for	and	consumption	of	non-nutritious	foodstuffs,	an	45	








The	 description	 of	 a	 third	 cannabinoid-sensitive	 receptor	 in	 2007	 called	 G-54	
protein-coupled	 receptor	 55	 (GPR55),	 brought	 the	 ECS	 again	 to	 the	 forefront	55	
with	the	hope	of	generating	anti-obesity	drugs	that	lacked	the	adverse	effects	of	56	
Rimonabant.	 GPR55	 is	 a	 classical	 rhodopsin-like	 seven	 transmembrane	 GPCR	57	
that	 despite	 showing	 cannabinoid	 sensitivity,	 shares	 less	 than	 15%	 sequence	58	
identity	 with	 the	 cannabinoid	 receptors	 and	 lacks	 the	 classical	 cannabinoid	59	
binding	pocket	[2].	Human	GPR55	shares	approximately	80%	sequence	identity	60	
with	 rat	 and	 mouse	 orthologs	 and	 is	 found	 at	 high	 levels	 in	 human	 spleen,	61	
intestines,	 stomach	 and	 brain	 [2].	 Research	 into	 GPR55	 expanded	 rapidly	 but	62	
erratically,	 resulting	 in	 a	 rather	 confusing	 pharmacological	 profile.	 GPR55	63	
certainly	 displays	 sensitivity	 to	 diverse	 cannabinoid	 compounds,	 including	64	
Rimonabant,	but	the	most	consistently	described	ligand	is	the	endogenous	lipid,	65	
lysophosphatidylinositol	 (LPI)	 [2].	 Following	 a	 recent	 nomenclature	 review	 of	66	
lysophospholipid-sensitive	receptors,	GPR55	has	been	provisionally	named	LPI1.	67	
It	 is	 now	 understood	 that	 several	 of	 the	 previously	 described	 physiological	68	
effects	of	LPI	are	mediated	via	GPR55	[2].	GPR55	couples	to	Gα13	G-proteins	to	69	







play	a	role	 in	regulating	human	body	weight.	 In	a	cohort	of	 Japanese	women,	a	77	
Gly195Val	 missense	 polymorphism	 of	 GPR55	 was	 associated	 with	 increased	78	
incidence	of	anorexia	nervosa	[3].	The	Gly195Val	mutation	appeared	to	reduce	-	79	
but	not	abolish	-	GPR55	function,	although	effects	on	receptor	expression	were	80	
not	 investigated	 [3].	 A	 separate	 study	 investigated	 GPR55	 expression	 and	81	
circulating	levels	of	LPI	in	lean,	obese	and	diabetic	individuals.	GPR55	in	visceral	82	
fat	 correlated	 with	 higher	 body	 fat	 percentage	 and	 overall	 weight,	 with	 the	83	
highest	 GPR55	 levels	 recorded	 in	 diabetic	 patients	 [4].	 Circulating	 plasma	 LPI	84	
levels	 also	 correlated	 with	 body	 fat	 percentage	 and	 overall	 weight	 [4].	85	
Interestingly,	these	associations	were	strong	in	female	participants	but	weak	or	86	
absent	 in	 males.	 	 There	 is,	 as	 yet,	 no	 explanation	 for	 the	 difference,	 although	87	
sexual	 dimorphism	 is	 not	 uncommon	 in	 the	 regulation	 of	 energy	 homeostasis.	88	
Furthermore,	 LPI	 induced	 Ca2+	 release	 in	 cultured	 primary	 adipocytes	 and	89	
increased	 the	 expression	 of	 genes	 involved	 in	 fat	 deposition	 in	 explants	 of	90	
visceral	 fat	 [4].	 In	 summary,	 clinical	 and	 in	 vitro	 studies	 suggest	 that	 GPR55	91	
activation	 by	 LPI	 might	 be	 linked	 to	 increased	 weight	 and	 fat	 deposition	 in	92	
humans,	 and	 pharmacological	 blockade	 of	 GPR55	 may	 be	 beneficial	 in	93	
controlling	excessive	weight	gain.		94	
	95	
Studies	 utilising	 GPR55-/-	 mice,	 however,	 report	 different	 effects	 of	 GPR55	 on	96	
body	weight	and	 insulin	sensitivity.	Genetic	deletion	of	GPR55	appears	 to	have	97	
no	 effect	 on	 overall	 body	 weight	 [5-7].	 However,	 one	 of	 these	 studies	 found	98	
increased	 fat	 deposition	 and	 insulin	 resistance	 in	 GPR55-/-	 mice	 due	 to	99	
decreased	physical	 activity,	while	 no	 significant	 change	 in	 food	 intake	 or	 body	100	
weight	was	observed	in	these	animals	[6].	Furthermore,	Moreno-Navarrete	et	al.	101	
[4]	report	that	ob/ob	mice	had	lower	levels	of	GPR55	mRNA	and	protein	in	white	102	




distinct	 species,	 making	 the	 translation	 between	 rodents	 and	 human	107	
problematic.	 As	 yet,	 no	 clear	 disparity	 in	 pharmacology	 or	 signalling	 between	108	
rodent	and	human	GPR55	has	been	described,	making	these	findings	difficult	to	109	
reconcile.	 However,	 whole-body	 GPR55	 knockout	 mice	 may	 have	 numerous	110	
compensatory	 changes	 in	 other	 genes	 that	 influence	 fat	 deposition	 and	111	
metabolism,	leading	to	contradictory	results.	Alternatively,	GPR55	knockout	may	112	
exert	effects	on	other	systems	that	ultimately	influence	adipose	physiology,	such	113	












islets	 and	 activation	 of	 the	 receptor	 increases	 insulin	 release	 from	 cultured	126	
rodent	 cells	 [9,	 10].	 Furthermore,	 GPR55	 agonists	 were	 shown	 to	 decrease	127	










of	 the	gut	 including	 the	duodenum,	 jejunum,	 ileum	and	 colon.	 It	 is	 known	 that	138	
GPR55	is	expressed	not	only	on	the	GI	endothelial	cells	but	also	on	the	myenteric	139	
neurons	 of	 the	 colon,	 suggesting	 that	 it	may	 play	 a	 role	 in	 GI	motility.	 Indeed,	140	
activation	 of	 GPR55	 appears	 to	 inhibit	 gut	 motility	 [11].	 Furthermore,	 GPR55	141	
also	 regulates	 intestinal	 inflammation.	 GPR55	 antagonists	 reduce	 intestinal	142	
inflammation	 in	 in	 vivo	 rodent	 models	 [12].	 These	 few	 studies	 raise	 the	143	
possibility	 that	 GPR55	 modulators	 may	 represent	 novel	 therapeutics	 for	144	






While	 research	 into	 the	 GPR55-LPI	 signalling	 axis	 in	 metabolism	 is	 gradually	151	
coming	 to	 fruition,	 it	 has	 already	 been	 shown	 to	 exert	multifarious	 effects	 on	152	
cancer.	 In	 the	 1980s,	 LPI	 was	 shown	 to	 be	 released	 from	 thyroid	 cells	 and	153	
fibroblasts	 that	 were	 transformed	 with	 the	 oncogene	 Ras.	 LPI	 released	 from	154	
cancer	cells	can	drive	cell	proliferation	via	autocrine	activation	of	GPR55	on	the	155	
cell	surface,	which	is	a	significant	finding	since	women	with	ovarian	cancer	have	156	
high	plasma	LPI	 levels	 [13].	GPR55	mRNA	is	expressed	 in	 tumors	 from	diverse	157	
human	cancers	ranging	 from	brain	 to	pancreatic	cancer	and	 is	expressed	more	158	
highly	 in	 breast	 and	 pancreatic	 tumors	 of	 high	 histological	 grade	 compared	 to	159	
low-grade	 and	 healthy	 tissue	 [14].	 GPR55	 appears	 to	 be	 a	 causative	 factor,	 as	160	
over-expression	 of	 GPR55	 in	 cancer	 cell	 lines	 leads	 to	 increased	 proliferation	161	
whereas	siRNA	knockdown	of	GPR55	renders	cells	less	proliferative	[14].	Taken	162	
together,	 these	 studies	 suggest	 that	 increased	 GPR55	 expression	 may	 induce	163	







Given	 the	 increasing	 global	 incidence	 of	 metabolic	 disorders,	 new	 drugs	 that	171	
lower	body	weight	and	improve	glucose	tolerance	are	desperately	needed.	While	172	
we	still	have	a	long	way	to	go,	GPR55	might	be	an	interesting	target	to	explore,	173	
given	 its	 expression	 in	 numerous	 metabolically	 important	 tissues	 in	 humans	174	
(Figure	1).	However,	prudence	is	required	in	extrapolating	findings	from	current	175	
rodent	models,	given	the	disparity	in	results	between	human	and	rodent	weight	176	
gain	 following	 GPR55	 perturbation.	 A	 more	 thorough	 understanding	 of	 the	177	
commonalities	and	differences	of	the	GPR55-LPI	signalling	axis	between	human	178	






















































Cannabidiol	 (CBD),	 a	 constituent	 of	Cannabis	 sativa	 plant,	 was	 one	 of	 the	 first	233	
described	GPR55	antagonists.	However,	CBD	is	not	selective	for	GPR55	and	has	234	
proved	 inconsistent	 in	blocking	GPR55-mediated	agonist	effects	 in	vitro,	 across	235	
different	 research	 groups.	 Recent	 studies	 have	 identified	 more	 selective	 and	236	
chemically	 distinct	 GPR55	 antagonists,	 ML193	 and	 CID16020046,	 through	237	
systematic	drug-screening	approaches.	ML193	has	nanomolar	potency	at	GPR55	238	
and	 more	 than	 145-fold	 selectivity	 over	 GPR35,	 its	 phylogenetic	 homologue.	239	
CID16020046	can	antagonise	a	chemically	diverse	range	of	GPR55	agonists	and	240	











Figure	1:	 	Comparison	of	 the	expression	and	 function	of	GPR55	 in	rodent	252	
and	human	metabolic	tissues	253	
The	 figure	 summarises	 our	 current	 understanding	 of	 the	 similarities	 and	254	
discrepancies	 (highlighted	 in	 bold)	 between	 rodent	 and	 human	 GPR55	255	
expression	and	function,	in	metabolically	important	tissues.	256	
	257	
	258	
